Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat

Karen Reckamp, MD
Published: Friday, Sep 14, 2012

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses a phase II study that evaluated the efficacy of the pretreatment serum test VeriStrat at predicting response to erlotinib (Tarceva) plus high-dose celecoxib (Celebrex) for patients with advanced non-small cell lung cancer (NSCLC).

The study randomized 107 patients with advanced NSCLC to receive erlotinib plus high-dose celecoxib or erlotinib and placebo. VeriStrat classifications were received for 96 patients and found a significant correlation between a Good VeriStrat status and disease control rate. Additionally, Good classifications more accurately predicted response and progression-free survival for patients receiving the combination of erlotinib and celecoxib, compared to erlotinib alone.

Reckamp is unsure why the VeriStrat analysis was more effective for the combination arm, since it has been validated for erlotinib alone. Overall, these results call for further trials to validate Veristrat's ability to determine which patients will benefit the most from the addition of high-dose celecoxib

<<< View coverage from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses a phase II study that evaluated the efficacy of the pretreatment serum test VeriStrat at predicting response to erlotinib (Tarceva) plus high-dose celecoxib (Celebrex) for patients with advanced non-small cell lung cancer (NSCLC).

The study randomized 107 patients with advanced NSCLC to receive erlotinib plus high-dose celecoxib or erlotinib and placebo. VeriStrat classifications were received for 96 patients and found a significant correlation between a Good VeriStrat status and disease control rate. Additionally, Good classifications more accurately predicted response and progression-free survival for patients receiving the combination of erlotinib and celecoxib, compared to erlotinib alone.

Reckamp is unsure why the VeriStrat analysis was more effective for the combination arm, since it has been validated for erlotinib alone. Overall, these results call for further trials to validate Veristrat's ability to determine which patients will benefit the most from the addition of high-dose celecoxib

<<< View coverage from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x